Skip to main content

Table 5 Prevalence of MTB detection by both Xpert MTB/RIF and PowerChek™ MTB/NTM Real-Time PCR assays, within groups with specific lung pathologies

From: Burden of respiratory tract infections at post mortem in Zambian children

  Xpert MTB/RIF Assay PowerChek™ MTB/NTM Assaya
  MTB detected MTB detected NTM detected
Overall 30 % (36/121) 16 % (12/73) 62 % (45/73)
Lung pathology    
Bronchopneumonia 30 % (18b/60) 9 % (3/35) 63 % (22/35)
Interstitial pneumonitis 60 % (8/20) 17 % (2/12) 67 % (8/12)
Tuberculosis (All forms) (PTB and/or EPTB) 30 % (3/10) 67 % (6/9) 22 % (2/9)
EPTB 100 % (1/1) 100 % (1/1) 0 % (0/1)
PTB 22 % (2/9) 63 % (5/8) 20 % (2/8)
Cytomegalovirus pneumonia 13 % (1/8) 0 % (0/4) 75 % (3/4)
Pneumocystis Jirovecii pneumonia 17 % (1/5) 0 % (0/3) 67 % (2/3)
Pulmonary oedema 33 % (2/6) 20 % (1/5) 80 % (4/5)
Candidiasis 0 % (0/3) 0 % (0/2) 50 % (1/2)
Acute respiratory distress 0 % (0/1) 0 % (0/1) 100 % (1/1)
Normal lungs 20 % (2/10) 0 % (0/7) 72 % (5/7)
  1. aThe PowerChek™ MTB/NTM Assay gave an ‘invalid’ result in 48 lung tissue specimens, even after repeat analysis
  2. bIncluding three rifampicin-resistant cases
  3. EPTB extrapulmonary tuberculosis, MTB Mycobacterium tuberculosis, NTM non-TB mycobacteria, PTB pulmonary tuberculosis